Aldeyra Therapeutics ALDX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Key Insights
Critical company metrics and information
Latest Closing Price
$6.35Market Cap
$379.15 MillionPrice-Earnings Ratio
-8.47Total Outstanding Shares
59.71 Million SharesTotal Employees
9Dividend
No dividendIPO Date
May 2, 2014SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
131 hartwell avenue, Lexington, MA, 02421Homepage
https://www.aldeyra.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-1.19 Million |
| Net Cash Flow From Investing Activities | $-43.35 Million |
| Net Cash Flow From Operating Activities | $-30.67 Million |
| Net Cash Flow From Operating Activities, Continuing | $-30.67 Million |
| Net Cash Flow From Financing Activities | $-1.19 Million |
| Net Cash Flow From Investing Activities, Continuing | $-43.35 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Net Income/Loss | $-44.80 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income/Loss From Continuing Operations After Tax | $-44.80 Million |
| Net Income/Loss Attributable To Parent | $-44.80 Million |
| Basic Average Shares | $59.54 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-44.73 Million |
| Comprehensive Income/Loss | $-44.73 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $66,540 |
| Other Comprehensive Income/Loss | $66,540 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $85.10 Million |
| Liabilities And Equity | $117.32 Million |
| Noncurrent Liabilities | $15.07 Million |
| Liabilities | $32.22 Million |
| Noncurrent Assets | $598,589 |
| Long-term Debt | $15.59 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ALDX from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.